Search
Lighting the Flame Journal Club
A learning and connecting hematology experience led by alumni of the Lighting the Flame program. The Lighting the Flame Journal Club is an online group that's open to all members of the Lighting the Flame community.
Read moreSWG Educational Activities
Symposium on ‘Aging and Hematology’Title‘Octogenarians, the oldest old. ’
Date and timeFriday, June 9, 2023, from 09:45-10:45. LocationRoom Fantasie, Frankfurt Messe, Frankfurt, Germany. Speakers
The scientist perspective—Kristina Kirschner (United Kingdom). The hematologist perspective—Valentin Goede (Germany).
Quality of Life and Symptoms
The goals of the SWG are:
To promote the evaluation of patient-reported outcomes (PROs) in hematology in daily clinical practice and in clinical trials.
Nomination Committee
Current committee members
Tony Green, United Kingdom (Chair)
Regular members
Maria Ester Bernardo, Italy
Jan Cools, Belgium
Sabine Eichinger, Austria
Shai Izraeli, Israel
Irene Roberts, United Kingdom
AimThe Nomination Committee (NC) is responsible for ensuring the quality of the EHA Board related to scientific and educational background, and balance…
Horizon 2020: The European Commission proposes the successor to Framework Programme 7
Horizons 2020 will pay “particular attention to ensuring a broad approach to innovation, which is not only limited to the development of new products and services on the basis of scientific and technological breakthroughs, but which also incorporates aspects such…
Read moreThe ‘i4MDS’ consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read moreEHA Award winners put in the spotlight in Copenhagen
The EHA-José Carreras Non-Clinical Junior Fellowship is made possible with the support of the German José Carreras Foundation.
Read moreDoes the patient with myelofibrosis feel better through Pacritinib?
Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.
Read moreMore than science: the European Affairs program at EHA2023
To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- »